Oligometastatic prostate cancer in the PSMA PET era: a state-specific narrative review of emerging therapeutic strategies
Prostate International · 2026-10
DOI: 10.1016/j.prnil.2026.10.001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Prostate International, 2026-10. Verfasst von Karan Sharma und 15 weiteren Autor:innen. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Oligometastatic prostate cancer occupies an intermediate position along the metastatic continuum but remains defined largely by pragmatic trial criteria rather than a discrete biology. Prostate-specific membrane antigen (PSMA) PET has increased detection of low-volume disease while destabilising conventional-imaging-based definitions, complicating cross-trial interpretation. This narrative review appraises practice-informing evidence through July 2026 using a state-specific framework. In metachronous oligorecurrent hormone-sensitive disease, metastasis-directed therapy (MDT) can delay systemic treatment in selected patients. Combining MDT with finite androgen deprivation therapy (ADT) improves disease control (RADIOSA, EXTEND), elective nodal radiotherapy improved metastasis-free survival relative to focal treatment for pelvic nodal recurrence in a phase II trial (PEACE V-STORM), and adding radium-223 to MDT did not improve progression-free survival in a small randomised trial (RAVENS). In de novo low-volume metastatic hormone-sensitive disease, an androgen-receptor-pathway-inhibitor-based systemic backbone is foundational. Prostate radiotherapy is evidence-based for conventionally staged low-volume disease, whereas cytoreductive prostatectomy remains investigational. In oligometastatic castration-resistant disease, GROUQ-PCS 9 and a long-term, unplanned analysis of ARTO provide hypothesis-generating randomised phase II signals, including an overall-survival signal for ARTO, that MDT can extend benefit from an active systemic regimen. TRAP supports further study of oligoprogression but lacks a control arm. PSMA-targeted radioligand therapy is established in metastatic castration-resistant disease and is moving into earlier states (LUNAR, BULLSEYE), although the evidence remains early-phase and overall-survival data from PSMAddition remain immature. Management should be organised by disease state, castration status, imaging platform, and systemic backbone rather than lesion count alone.
Zitieren
APA
Sharma, K., Al-Khanaty, A., Dinneen, E., Delgado, C., Chen, D., Eapen, R., Buteau, J., Hofman, M. S., Lawrentschuk, N., Spain, L., Azad, A. A., Ali, M., Au, L., Siva, S., Murphy, D. G., & Perera, M. (2026). Oligometastatic prostate cancer in the PSMA PET era: a state-specific narrative review of emerging therapeutic strategies. Prostate International. https://doi.org/10.1016/j.prnil.2026.10.001
Vancouver
Sharma K, Al-Khanaty A, Dinneen E, Delgado C, Chen D, Eapen R, et al. Oligometastatic prostate cancer in the PSMA PET era: a state-specific narrative review of emerging therapeutic strategies. Prostate International. 2026. doi:10.1016/j.prnil.2026.10.001
BibTeX
@article{Sharma2026,
author = {Sharma, Karan and Al-Khanaty, Abdullah and Dinneen, Eoin and Delgado, Carlos and Chen, David and Eapen, Renu and Buteau, James and Hofman, Michael S. and Lawrentschuk, Nathan and Spain, Lavinia and Azad, Arun A. and Ali, Muhammad and Au, Lewis and Siva, Shankar and Murphy, Declan G. and Perera, Marlon},
title = {Oligometastatic prostate cancer in the PSMA PET era: a state-specific narrative review of emerging therapeutic strategies},
journal = {Prostate International},
year = {2026},
doi = {10.1016/j.prnil.2026.10.001}
}
EUVIMED